Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD30 CAR-T in CD30+ Relapsed/Refractory Lymphoma
NCT07048353Phase 1Suspended
- Sponsor
- Shandong Qilu Stem Cell Engineering
- Start
- Mar 2026
- Primary completion
- Jul 2029
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CD30 CAR-T cells (Shandong Qilu) in lymphoma (3 arms), sponsored by Shandong Qilu Stem Cell Engineering. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 28 days. Started Mar 2026; status: suspended.
02
Drugs
CD30 CAR-T cells (Shandong Qilu)
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT07048353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07048353.